Cargando…

Cost-Effectiveness of Vonoprazan- and Rifabutin-Based Regimens

Detalles Bibliográficos
Autor principal:	Almenoff, June
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2023
Materias:	Correspondences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392884/ https://www.ncbi.nlm.nih.gov/pubmed/37094105 http://dx.doi.org/10.14309/ajg.0000000000002248

Ejemplares similares

Effectiveness of vonoprazan-based regimens compared with proton pump inhibitor-based regimens as first-line Helicobacter pylori agents
por: Kakiuchi, Toshihiko
Publicado: (2023)

Rifabutin and Furazolidone Could Be the Candidates of the Rescue Regimen for Antibiotic-Resistant H. pylori in Korea
por: Choi, Youn I, et al.
Publicado: (2019)

Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir
por: Moultrie, Harry, et al.
Publicado: (2015)

Rescue therapy with rifabutin regimen for refractory Helicobacter pylori infection with dual drug-resistant strains
por: Kuo, Chia-Jung, et al.
Publicado: (2020)

Rifabutin-based High-dose Proton-pump Inhibitor and Amoxicillin Triple Regimen as the Rescue treatment for Helicobacter pylori
por: Lim, Hyun Chul, et al.
Publicado: (2014)

Comparison of Rifabutin-Based Versus Rifampin-Based Regimens for the Treatment of Mycobacterium avium Complex: A meta-Analysis Study
por: Hajikhani, Bahareh, et al.
Publicado: (2021)

Effects of Voriconazole on the Pharmacokinetics of Vonoprazan in Rats
por: Shen, Jiquan, et al.
Publicado: (2020)

Effect of Rifabutin in Dolutegravir Dosing: A Case Series
por: Mendoza, Maria A., et al.
Publicado: (2022)

1360. Disseminated Mycobacterium abscessus Infections in Patients with Neutralizing Anti-interferon-gamma Autoantibodies Treated with Rifabutin-based Combination Regimens
por: Cheng, Aristine, et al.
Publicado: (2019)

A randomized clinical study on the efficacy of vonoprazan combined with amoxicillin duo regimen for the eradication of Helicobacter pylori
por: Yang, Faming, et al.
Publicado: (2023)

Rifabutin Is Active against Mycobacterium abscessus Complex
por: Aziz, Dinah Binte, et al.
Publicado: (2017)

Rifabutin Is Active against Mycobacterium abscessus in Mice
por: Dick, Thomas, et al.
Publicado: (2020)

Safety of Rifabutin in patients with rifampicin-induced thrombocytopenia
por: Sarkar, Trina, et al.
Publicado: (2020)

Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan
por: Habu, Yasuki
Publicado: (2019)

Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in China
por: Wang, Zhenhua, et al.
Publicado: (2022)

Efficacy and safety of low‐dose rifabutin‐based 7‐day triple therapy as a third‐ or later‐line Helicobacter pylori eradication regimen
por: Inokuchi, Kazumi, et al.
Publicado: (2022)

Safety and effectiveness of vonoprazan-based rescue therapy for Helicobacter pylori infection
por: Yu, Jing, et al.
Publicado: (2023)

Vonoprazan on the Eradication of Helicobacter pylori Infection
por: Huang, Jiaming, et al.
Publicado: (2023)

Efficacy of Vonoprazan for Helicobacter pylori Eradication
por: Kiyotoki, Shu, et al.
Publicado: (2019)

Vonoprazan‐associated long QT syndrome
por: Kubo, Kimitoshi, et al.
Publicado: (2021)

The role of vonoprazan in patients with erosive esophagitis
por: Zhang, Mengyu, et al.
Publicado: (2022)

Comparison of eradication rates of moxifloxacin–rifabutin triple therapy and bismuth quadruple therapy as second‐line regimens in patients with peptic ulcers
por: Lee, Chang Min, et al.
Publicado: (2022)

Ex Vivo Human Placental Transfer of Rifampin and Rifabutin
por: Magee, Kevin P., et al.
Publicado: (1996)

Bilateral uveitis associated with concurrent administration of rifabutin and nelfinavir
por: Cheng, Wen-Hsin, et al.
Publicado: (2015)

Tuberculosis-HIV treatment with rifampicin or rifabutin: are the outcomes different?
por: Schmaltz, Carolina Arana Stanis, et al.
Publicado: (2019)

Rifabutin for the Treatment of Helicobacter pylori Infection: A Review
por: Gisbert, Javier P.
Publicado: (2020)

Comments regarding use of rifabutin for Helicobacter pylori eradication
por: Graham, David Y.
Publicado: (2021)

In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action and resistance mechanisms
por: Trebosc, Vincent, et al.
Publicado: (2020)

A Vonoprazan, Clarithromycin, and Metronidazole Regimen as Helicobacter pylori Eradication Therapy for Patients with Penicillin Allergy in Light of Clarithromycin Resistance
por: Adachi, Kazunori, et al.
Publicado: (2023)

Importance of Metronidazole in Vonoprazan-based Helicobacter pylori Treatment in Japan
por: Suzuki, Sho, et al.
Publicado: (2023)

Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial
por: Maruyama, Masafumi, et al.
Publicado: (2017)

Effects of Simvastatin on the Metabolism of Vonoprazan in Rats Both in vitro and in vivo
por: Hong, Yun, et al.
Publicado: (2022)

The Effect of Food on the Pharmacokinetics of the Potassium‐Competitive Acid Blocker Vonoprazan
por: Mulford, Darcy J., et al.
Publicado: (2021)

Comment On: Vonoprazan on the Eradication of Helicobacter pylori Infection
por: Düzenli, Tolga, et al.
Publicado: (2023)

A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis
por: Kim, Manse, et al.
Publicado: (2022)

Successful Anticoagulation With Warfarin After Switching From Rifampin to Rifabutin
por: Alnewais, Marwah E., et al.
Publicado: (2023)

The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks
por: Sirgel, Frederick A., et al.
Publicado: (2013)

Recurrent neutropenia induced by rifabutin in a renal transplant recipient
por: Chang, Ji Yeun, et al.
Publicado: (2014)

Rifabutin Use in Staphylococcus Biofilm Infections: A Case Series
por: Doub, James B., et al.
Publicado: (2020)

Rifabutin: A Repurposing Candidate for Mycobacterium abscessus Lung Disease
por: Dick, Thomas
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_702gggb6f92rldbs6qi1vvnce8